Manufactures vaccines for diseases like hepatitis, influenza, rubella and typhoid fever

Inhibitex, Inc. operates as an clinical-stage biopharmaceutical company. The firm develops differentiated anti-infective products to prevent or treat serious infections. Its research and development efforts are currently focused on oral, small molecule compounds to treat viral infections, and in particular, chronic infections caused by HCV and herpes zoster. The company was founded by Joseph M. Patti in May 1994 and is headquartered in Alpharetta, GA.

Biological research

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

iNtRON Biotechnology, Inc. engages in the development of super-bacteria treatment, antibiotics alternatives, bio new drug, molecular diagnostics and artificial blood. Its products include anti-bacterial agents, identification kits, research reagents and kits. The company was founded on January 18, 1999 and is headquartered in Seongnam-si, South Korea.

NeuTec Pharma Ltd. develops biopharmaceutical products. It specializes in the development of genetically recombinant antibodies, or “grabs”, for the treatment of life-threatening infections. The firm's products include Mycograb and Aurograb. The company was founded in 1997 and is headquartered in Camberley, the United Kingdom.

Versitech Ltd. is a Hong Kong Chinese company located in Hong Kong and ultimately controlled by the Government of Hong Kong Special Administrative Region. The firm provides business services.

Bharat Biotech International Ltd. engages in research and development, manufacturing, marketing and distribution of vaccines and biotherapeutics. It focuses on the development of novel health care solutions for region-specific neglected diseases. The firm offers Revac-B+, REGEN-D, HNVAC, COMVAC5, BIOPOLIO, INDIRAB, Typbar TCV, BIOHIB, JENVAC, ROTAVAC and vaccine candidates against chikungunya, chandipura, HPV and Ebola. The company was founded by Krishna Murthy Ella and Suchitra K. Ella in 1996 and is headquartered in Hyderabad, India..

Human Genome Sciences, Inc. is a biopharmaceutical company that exists to place new therapies into the hands of those battling serious disease. Its lead products include BENLYSTA for systemic lupus erythematosus and raxibacumab for inhalation anthrax. The firm's other products include, mapatumumab, darapladib, albiglutide, ZALBIN, HGS1036 and HGS1029. The company was founded by Alan G. Walton and William A. Haseltine in 1992 and is headquartered in Gaithersburg, MD.

XBiotech is a biopharmaceutical company developing first-in-class antibody therapies. The Company’s lead product candidate inhibits chronic (sterile) inflammation – a condition involved in the progression of many serious and common diseases. The Company has several groundbreaking clinical trial programs in different areas of medicine including dermatology, oncology, diabetes, cachexia and cardiovascular disease.

MedImmune develops medicines for unmet medical needs worldwide. As the global biologics research and development arm of AstraZeneca, MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. Since its founding in 1988, MedImmune has remained committed to scientific innovation and medical progress, continually looking beyond standard expectations and pushing the boundaries of what is possible.

Part of Gestion Socpra, Inc., SOCPRA-Sciences et Génie S.E.C. is a Canadian company located in Sherbrooke, QC, that manages research intellectual property.

Gladskin contains billions of bacteria, of which the vast majority protects our skin. To maintain a healthy skin environment, it is necessary to maintain a good bacterial balance. The disruption of this balance can result in, or aggravate, skin conditions. Traditional skin products and antibiotics do not differentiate between good and bad bacteria, and therefore also remove the beneficial bacteria that protect us. Gladskin contains Staphefekt.

NXXI, Inc. operates as a nutritional bioscience company. It primarily develops and markets raw materials, formulations, compounds, blends and bulk and other materials to third-party non-end users to be further fabricated, blended or packaged for ultimate sales to end-users as nutritional supplements. The company was founded on June 29, 1983 and is headquartered in Purchase, NY.

Integrated BioTherapeutics is a biotechnology company that focuses on discovering novel vaccines and therapeutics for emerging infectious diseases. Its antiviral pipeline includes unique pan-filovirus antibody candidates, vaccines, and a variety of other product candidates for emerging viruses.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Smithkline Beckman Corp, part of GSK Plc, is an American company located in Philadelphia, PA, involved in pharmaceutical preparations. On July 27, 1989 Smithkline Beecham Plc acquired Smithkline Beckman Corp for $16,082.37 million.

Biosynexus, Inc. develops and markets pharmaceutical products. The company is headquartered in Rockville, MD.

Humabs currently has two clinical-stage partnered programs, validating the CellClone technologies and generating a significant revenue stream Humabs has a broad partnership with MedImmune, the global biologics research and development arm of AstraZeneca, that covers multiple pathogens. The most advanced of the projects is an antibody directed against influenza A virus. This antibody, called MEDI8852, has demonstrated activity against all known subtypes of the influenza A virus and is therefore less affected by the emergence of new strains. The program was partnered with MedImmune while still in preclinical development and has currently concluded the clinical phase 1b/2a. Data on this program have been published in the journals Science and Cell. Humabs has also partnered with Novartis for an antibody directed against an undisclosed target. This program is currently in phase 2.